).
drug class allergy. PCN allergy is reported in up to 8% of individuals accessing care in the United States. 8 Although the majority of patients with a self-reported PCN allergy do not have a true allergy, 9 physicians may be reticent to administer a β-lactam antibiotic in this setting. No consistent recommendations regarding the appropriate antibiotic regimen to use in cases of PPROM in a patient with a PCN allergy exist. Also, some physicians may prefer non-β-lactam regimens for management of PPROM. However, data regarding the impact of alternative antibiotic regimen on neonatal morbidity and mortality as well as maternal infectious morbidity are unavailable. The objective of this study was to assess the impact of a non-β-lactam antibiotic regimen in expectant management of PPROM on neonatal morbidity and mortality. Additionally, we sought to describe impact of non-β-lactam antibiotic regimen on pregnancy latency and maternal infectious outcomes.
Methods
This study is a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal-Fetal Medicine Units Network, beneficial effects of antenatal magnesium sulfate (BEAM) randomized, placebo controlled, and multicenter trial of antenatal magnesium sulfate for the prevention of cerebral palsy. 10 Duke
University institutional review board determined the study to be exempt under protocol Pro00065517. We included singleton, nonanomalous pregnancies complicated by PPROM at or beyond 24 0/7 weeks of gestation and delivery at less than 35 0/7 weeks. The gestational age of 35 weeks was selected to minimize exclusion of women with PPROM who were induced starting at 34 weeks. We excluded multiple gestations, pregnancies complicated by chromosomal abnormalities, pregnancies where no antibiotics were administered, and those subjects with a missing date or time of rupture or delivery. Women receiving the gold standard antibiotic regimen β-lactam and macrolide were compared with women receiving a non-β-lactam and macrolide regimen. PCN and cephalosporin antibiotic regimens were both included in the β-lactam group given their similar mechanism of action and similar hypersensitivity response. The primary outcome was a neonatal composite of severe necrotizing enterocolitis (NEC; defined as grade 2 or 3), severe intraventricular hemorrhage (defined as grade 4), periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), neonatal death prior to hospital discharge, sepsis, and cerebral palsy. Our secondary outcomes included all the components of the composite, pregnancy latency, and maternal endometritis and chorioamnionitis. Pregnancy latency was defined as the interval of time in days from membrane rupture to delivery.
The characteristics and outcomes of subjects receiving the different antibiotic regimens were compared using KruskalWallis, Chi-squared or Fisher's exact test as appropriate. Multivariable logistic regression models for the outcomes of interest were then developed to estimate the true effect of the β-lactam and macrolide versus non-β-lactam antibiotic The primary neonatal composite outcome occurred in 28.3% of the β-lactam and macrolide group and 35.2% of the non-β-lactam and macrolide group (p ¼ 0.11). When the individual components of the neonatal composite were analyzed, with the exception of severe necrotizing enterocolitis, neonates receiving the β-lactam and macrolide group trended toward a reduction in adverse outcomes, with bronchopulmonary dysplasia reaching clinical significance (p ¼ 0.03; ►Table 3). With regards to severe necrotizing enterocolitis, the inverse was seen (p ¼ 0.04). In adjusted analyses, no difference between groups for the neonatal composite (adjusted odds ratio [AOR] ¼ 0.50; 95% confidence interval [CI]: 0.22-1.11) was found when adjusting for maternal age, race, maternal drug use, neonatal gender, gestational age at birth, birth weight, magnesium exposure, clindamycin exposure, and corticosteroids
Regarding maternal outcomes, risk of chorioamnionitis and endometritis did not differ, nor did the median latency (6.9 days [IQR: 3.4-13.5] vs. 7.0 days [IQR: 3.3-15.4]; ►Table 3). After controlling for confounders, the risk for chorioamnionitis remained nonsignificant (►Table 4). However, women receiving the gold standard antibiotic regimen were less likely to get endometritis, (AOR ¼ 0.35; 95% CI: 0.14-0.91).
Discussion
Among women with pregnancies affected by PPROM, receiving a non-β-lactam and macrolide containing antibiotic regimen was associated with increased risk of endometritis. Neonates born to women who received the gold standard antibiotic regimen of a β-lactam and macrolide were less likely to have bronchopulmonary dysplasia but more likely to have severe necrotizing enterocolitis.
Our findings suggest improved neonatal outcomes with administration of β-lactam antibiotics in PPROM those are supported by previous research. The current standard of care for antibiotic administration in PPROM was established based on the results from a large, multicenter, randomized controlled trial evaluating use of ampicillin and erythromycin on a composite neonatal outcome. 3 In that study, a decrease in composite neonatal morbidity, respiratory distress, necrotizing enterocolitis, sepsis, pneumonia, patent ductus arteriosus, bronchopulmonary dysplasia, and hyperbilirubinemia with β-lactam and macrolide antibiotic administration was seen. Our study is furthermore unique given the finding of decreased risk of endometritis in women receiving a β-lactam containing antibiotic regimen. Previous studies have shown that antibiotics in general decrease maternal chorioamnionitis and pregnancy latency in the setting PPROM. 4, 7, 11 However, previous studies have not shown decreased rates of endometritis. 5, 6 However, other postpartum infectious morbidities have been shown to be more common among women receiving non-β-lactam regimens.
12
The trend toward increasing severe necrotizing enterocolitis in the neonates receiving a β-lactam regimen in both analyses is not novel. Previous studies have demonstrated an increased risk of necrotizing enterocolitis with coamoxiclav, as well as with ampicillin.
13,14 A plausible mechanism of action for the development of necrotizing enterocolitis in this population is alteration in the neonatal intestinal mircobiome. 15 Several studies have shown that maternal antepartum antibiotic administration has altered neonatal intestinal bacterial colonization. 16, 17 Their newborn's intestinal mircobiome may also be altered and predispose the neonate to necrotizing enterocolitis. The participants in the non-β-lactam group were exposed to alternative antibiotics and it is possible exposure to these antibiotics confounds our results. One of the most common antibiotics women in the non-β-lactam group received was clindamycin. Formulations of this antibiotic containing the preservative benzyl alcohol have been associated with adverse neonatal outcomes related to "gasping syndrome." 18, 19 "Gasping syndrome" has been reported in premature infants exposed to clindamycin and results in multisystem organ failure and often death. 19 Although we cannot determine the specific formulations that neonates in out cohort received, it is possible that women in the non-β-lactam group suffered adverse neonatal morbidities from their antibiotic exposure that were not quantified in our study. We recognize other limitations to our study. As a retrospective cohort study, we are inherently limited to observational data, such as, we cannot assess causation. Additionally, given we performed a secondary analysis of the BEAM trial of antenatal magnesium sulfate for the prevention of cerebral palsy, we are limited in our analysis by the data that were collected for the primary analysis. For example, we do not have data on the timing of antibiotic administration in relation to PPROM, labor, and delivery; antibiotic dosing, total doses, and frequency of dosing. Our study design of a secondary analysis also limited our sample size and a post hoc power analysis demonstrated that the study was underpowered to show a difference. We detected at 24% increase in the primary outcome in the non-β-lactam and macrolide group. However, based on the ratio of women in β-lactam and macrolide group to non-β-lactam and macrolide group (roughly 7:1), we would need 2,767 women in the β-lactam group and 415 women in the non-β-lactam and macrolide group to detect a difference in the primary outcome. However, our findings are hypothesis generating and suggest need for further study. Also, we did have to exclude a large number of patients for either incomplete data or administration of a β-lactam antibiotic without a macrolide. Finally, we were unable to compare PCNs versus cephalosporins on maternal or neonatal outcomes given they were analyzed together as β-lactam antibiotics.
Our study also has several strengths. First, large sample size decreases risk of type 2 error. Also, because the original data were collected from multiple centers nationwide by trained data abstractors, the data represent a diverse patient population and the results are more likely to be generalized. Finally, as there is limited data available in the literature regarding the efficacy of a non-β-lactam regimen on women with PPROM, this study adds information for the clinician that is applicable in daily practice. 
Conclusion
In conclusion, women with PPROM receiving a β-lactam and macrolide were less likely to suffer from endometritis. Additionally, among neonates with PPROM the administration of a β-lactam antibiotics did not impact composite neonatal morbidity. However, alterations in individual neonatal morbidities suggest that follow-up studies are needed to further investigate the effects of non-β-lactam antibiotic regimens on pregnancies affected by PPROM. Given these associations, practitioners should appropriately use cephalosporins in patients with a nonsignificant PCN allergy and should consider PCN allergy testing in all pregnant women with significant allergies to optimize maternal and neonatal outcomes in pregnancies affected by PPROM in the setting of PCN allergy.
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